S-23
Status
In trials. No FDA-approved labeling exists. No human clinical development is listed in this site's sources, and no approval elsewhere is listed in this site's sources.
What it is
A SARM studied in animals as a potential male contraceptive.
What published research measured
A selective androgen receptor modulator with higher binding affinity than most of the class, studied in rodents where it produced dose-dependent suppression of follicle stimulating hormone and luteinising hormone complete enough that it was investigated as a candidate male contraceptive — spermatogenesis was fully suppressed and recovered after withdrawal. That is the clearest published signal about what this compound does, and it is worth reading directly: the animal evidence for potent gonadal suppression is stronger than the animal evidence for any body composition benefit. No published human trial of S-23 was identified — no efficacy data, no pharmacokinetics, no safety data in people. Prohibited at all times in sport under WADA class S1.2.
Source
Jones et al., S-23 rodent male contraceptive studies
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.